STRASBOURG, France–(BUSINESS WIRE)– Regulatory News:
Transgene (Paris:TNG) today announced that management will participate
in the upcoming investor events outlined below:
-
Rodman & Renshaw 18th Global
Investment Conference: September 12 & 13, 2016 – New York, USA
- Mid Cap Event: October 5 & 6, 2016 – Paris, France
- Actionaria: November 18 & 19, 2016 – Paris, France
- Natixis Mid Cap Conference: November 22, 2016 – Paris, France
Next financial communication:
Financial results for the first six months of 2016 and business update:
September
5, 2016 after market close
About Transgene
Transgene S.A. (Euronext: TNG), part
of Institut Mérieux, is a publicly traded French biopharmaceutical
company focused on designing and developing targeted immunotherapies for
the treatment of cancer and infectious diseases. Transgene’s programs
utilize viral vector technology with the goal of indirectly or directly
killing infected or cancerous cells. The Company’s two lead
clinical-stage programs are: TG4010 for non-small cell lung cancer and
Pexa-Vec for liver cancer. The Company has several other programs in
clinical and pre-clinical development. Transgene is based in Strasbourg,
France, and has additional operations in Lyon, as well as a joint
venture in China. Additional information about Transgene is available at www.transgene.fr.
Follow us on Twitter: @TransgeneSA
View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005930/en/
Contacts
Transgene:
Lucie Larguier, +33 (0)3 88 27 91 04
Director
Corporate Communications & IR
investorrelations@transgene.fr
or
Media
contacts:
Citigate Dewe Rogerson
David Dible /
Marine Perrier, + 44 (0)20 7638 9571
transgene@citigatedr.co.uk
Source: Transgene
Cet article Transgene Announces Participation at Upcoming Investor Events est apparu en premier sur EEI-BIOTECHFINANCES.